Combination immunotherapy of PEG-modified preladenant thermosensitive liposomes and PD-1 inhibitor effectively enhances the anti-tumor immune response and therapeutic effects

References

• Allard B, Turcotte M, Stagg J. 2012. CD73-generated adenosine: orchestrating the tumor-stroma interplay to promote cancer growth. J Biomed Biotechnol. 2012:485156.
   PubMedGoogle Scholar
• Altundag K. 2019. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 380(10):986–987.
   PubMedGoogle Scholar
• Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC, et al. 2018. Understanding the tumor immune microenvironment (time) for effective therapy. Nat Med. 24(5):541–550.
   PubMed Web of Science ®Google Scholar
• Borea P, Gessi S, Merighi S, Varani K. 2016. Adenosine as a multi-signalling guardian angel in human diseases: when, where and how does it exert its protective effects? Trends Pharmacol Sci. 37(6):419–434.
   PubMed Web of Science ®Google Scholar
• Borea P, Varani K, Vincenzi F, Baraldi P, Tabrizi M, Merighi S, Gessi S. 2015. The A3 adenosine receptor: history and perspectives. Pharmacol Rev. 67(1):74–102.
   PubMed Web of Science ®Google Scholar
• Claff T, Klapschinski T, Tiruttani Subhramanyam U, Vaaßen V, Schlegel J, Vielmuth C, Voß J, Labahn J, Müller C. 2022. Single stabilizing point mutation enables high-resolution co-crystal structures of the adenosine a receptor with preladenant conjugates. Angew Chem Int Ed Engl. 61(22):e202115545.
   PubMed Web of Science ®Google Scholar
• Cutler D, Tendolkar A, Grachev I. 2012. Safety, tolerability and pharmacokinetics after single and multiple doses of preladenant (SCH420814) administered in healthy subjects. J Clin Pharm Ther. 37(5):578–587.
   PubMed Web of Science ®Google Scholar
• Finck A, Gill SI, June CH. 2020. Cancer immunotherapy comes of age and looks for maturity. Nat Commun. 11(1):4.
   PubMed Web of Science ®Google Scholar
• Fredholm B, Ijzerman A, Jacobson K, Linden J, Müller C. 2011. International union of basic and clinical pharmacology. LXXXI. Nomenclature and classification of adenosine receptors – an update. Pharmacol Rev. 63(1):1–34.
   PubMed Web of Science ®Google Scholar
• Galon J, Bruni D. 2019. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 18(3):197–218.
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, et al. 2015. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 373(1):23–34.
   PubMed Web of Science ®Google Scholar
• Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et al. 2015. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 372(26):2509–2520.
   PubMed Web of Science ®Google Scholar
• Linden J. 2005. Adenosine in tissue protection and tissue regeneration. Mol Pharmacol. 67(5):1385–1387.
   PubMed Web of Science ®Google Scholar
• Lyons TG. 2019. Targeted therapies for triple-negative breast cancer. Curr Treat Opt Oncol. 20(11):13.
   PubMed Web of Science ®Google Scholar
• Offermanns S, Colletti S, Lovenberg T, Semple G, Wise A, Ijzerman A. 2011. International union of basic and clinical pharmacology. LXXXII: nomenclature and classification of hydroxy-carboxylic acid receptors (GPR81, GPR109a, and GPR109b). Pharmacol Rev. 63(2):269–290.
   PubMed Web of Science ®Google Scholar
• Peng S, Xiao F, Chen M, Gao H. 2022. Tumor-microenvironment-responsive nanomedicine for enhanced cancer immunotherapy. Adv Sci. 9(1):e2103836.
   Web of Science ®Google Scholar
• Rodallec A, Sicard G, Fanciullino R, Benzekry S, Lacarelle B, Milano G, Ciccolini J. 2018. Turning cold tumors into hot tumors: harnessing the potential of tumor immunity using nanoparticles. Expert Opin Drug Metab Toxicol. 14(11):1139–1147.
   PubMed Web of Science ®Google Scholar
• Sarpoli L, Zare-Karizi S, Heidari E, Hasanzadeh A, Bayandori M, Azedi F, Hamblin M, Karimi M. 2022. Co-delivery of curcumin and Bcl-2 siRNA to enhance therapeutic effect against breast cancer cells using PEI-functionalized PLGA nanoparticles. Pharm Dev Technol. 27(7):785–793.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. 2019. Cancer Statistics, 2019. CA Cancer J Clin. 69(1):7–34.
   PubMed Web of Science ®Google Scholar
• Toh JWT, De Souza P, Lim SH, Singh P, Chua W, Ng W, Spring KJ. 2016. The potential value of immunotherapy in colorectal cancers: review of the evidence for programmed death-1 inhibitor therapy. Clin Colorectal Cancer. 15(4):285–291.
   PubMed Web of Science ®Google Scholar
• Tomita M, Suzuki M, Kono Y, Nakajima K, Matsuda T, Kuge Y, Ogawa M. 2020. Influence on [F-18]FDG uptake by cancer cells after anti-PD-1 therapy in an enforced-immune activated mouse tumor. EJNMMI Res. 10(1):10.
   PubMed Web of Science ®Google Scholar
• Van Waarde A, Dierckx R, Zhou X, Khanapur S, Tsukada H, Ishiwata K, Luurtsema G, De Vries E, Elsinga P. 2018. Potential therapeutic applications of adenosine a receptor ligands and opportunities for A2A receptor imaging. Med Res Rev. 38(1):5–56.
   PubMed Web of Science ®Google Scholar
• Vonnemann J, Beziere N, Böttcher C, Riese SB, Kuehne C, Dernedde J, Licha K, von Schacky C, Kosanke Y, Kimm M, et al. 2014. Polyglycerolsulfate functionalized gold nanorods as optoacoustic signal nanoamplifiers for in vivo bioimaging of rheumatoid arthritis. Theranostics. 4(6):629–641.
   PubMed Web of Science ®Google Scholar
• Wang L, Yu X, Wang C, Pan S, Liang B, Zhang Y, Chong X, Meng Y, Dong J, Zhao Y, et al. 2017. The anti-ErbB2 antibody H2-18 and the pan-PI3K inhibitor GDC-0941 effectively inhibit trastuzumab-resistant ErbB2-overexpressing breast cancer. Oncotarget. 8(32):52877–52888.
   PubMedGoogle Scholar
• Xu Y, Xiong J, Sun X, Gao H. 2022. Targeted nanomedicines remodeling immunosuppressive tumor microenvironment for enhanced cancer immunotherapy. Acta Pharm Sin B. 12(12):4327–4347.
   PubMed Web of Science ®Google Scholar
• Young A, Mittal D, Stagg J, Smyth M. 2014. Targeting cancer-derived adenosine: new therapeutic approaches. Cancer Discov. 4(8):879–888.
   PubMed Web of Science ®Google Scholar
• Young A, Ngiow SF, Gao Y, Patch A-M, Barkauskas DS, Messaoudene M, Lin G, Coudert JD, Stannard KA, Zitvogel L, et al. 2018. A2AR adenosine signaling suppresses natural killer cell maturation in the tumor microenvironment. Cancer Res. 78(4):1003–1016.
   PubMed Web of Science ®Google Scholar
• Zhang D, Zhang J, Li Q, Song A, Li Z, Luan Y. 2019. Cold to hot: rational design of a minimalist multifunctional photo-immunotherapy nanoplatform toward boosting immunotherapy capability. ACS Appl Mater Interfaces. 11(36):32633–32646.
   PubMed Web of Science ®Google Scholar
• Zhou J, Guo B, Zhu W, Sui X, Ma X, Qian J, Cao L, Han C. 2021. In vitro novel biomimetic nanostructured lipid carriers for cancer therapy: preparation, characterization, and/evaluation. Pharm Dev Technol. 26(1):81–91.
   PubMed Web of Science ®Google Scholar